In brief: Suspension of Johnson & Johnson COVID-19 vaccine lifted.
出版信息
Med Lett Drugs Ther. 2021 May 17;63(1624):e1.
PMID:33976095
Abstract
摘要
相似文献
1
In brief: Suspension of Johnson & Johnson COVID-19 vaccine lifted.
Med Lett Drugs Ther. 2021 May 17;63(1624):e1.
2
In brief: Johnson & Johnson COVID-19 vaccine suspended.
Med Lett Drugs Ther. 2021 May 3;63(1623):e1.
3
FDA authorizes Johnson & Johnson COVID-19 vaccine.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):41-42.
4
In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):145-146.
5
In brief: Guillain-Barré syndrome with the Johnson and Johnson COVID-19 vaccine.
Med Lett Drugs Ther. 2021 Aug 9;63(1630):121.
6
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.
7
Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply.
Ann Intern Med. 2021 Apr;174(4):570-572. doi: 10.7326/M20-8137. Epub 2021 Jan 5.
8
Answering Key Questions About COVID-19 Vaccines.
JAMA. 2020 Nov 24;324(20):2027-2028. doi: 10.1001/jama.2020.20590.
9
Vaccine safety - is the SARS-CoV-2 vaccine any different?
Hum Vaccin Immunother. 2021 May 4;17(5):1322-1325. doi: 10.1080/21645515.2020.1829414. Epub 2020 Dec 3.
10
Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.
J Am Acad Dermatol. 2021 Nov;85(5):1113-1116. doi: 10.1016/j.jaad.2021.08.031. Epub 2021 Aug 23.
Zotero 插件